AViTA Corporation (TPEX:4735)
Taiwan · Delayed Price · Currency is TWD 34.40
0.00 (0.00%)
Sep 12, 2025, 1:30 PM CST
AViTA Revenue
AViTA had revenue of 253.54M TWD in the quarter ending June 30, 2025, a decrease of -0.36%. This brings the company's revenue in the last twelve months to 929.79M, up 13.87% year-over-year. In the year 2024, AViTA had annual revenue of 927.30M with 5.48% growth.
Revenue (ttm)
929.79M
Revenue Growth
+13.87%
P/S Ratio
1.42
Revenue / Employee
11.07M
Employees
84
Market Cap
1.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 927.30M | 48.22M | 5.48% |
| Dec 31, 2023 | 879.08M | -321.84M | -26.80% |
| Dec 31, 2022 | 1.20B | -1.12B | -48.35% |
| Dec 31, 2021 | 2.33B | -274.96M | -10.57% |
| Dec 31, 2020 | 2.60B | 1.35B | 108.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.83M |
| PharmaEssentia | 12.63B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Lumosa Therapeutics | 37.25M |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Center Laboratories | 1.60B |